Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

Sanofi’s Sarclisa accepted for FDA priority review

May 29, 2024 Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review

Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
News

Merck shares data from phase 3 trial of Keytruda for TNBC treatment

May 29, 2024 Medical Communications Merck, Oncology, breast cancer, clinical trial, keytruda

Merck, known as MSD outside of the US and Canada, has announced results from the phase 3 KEYNOTE-522 trial, which …
News

AstraZeneca shares results from phase 3 TROPION-Lung01 trial

May 28, 2024 Medical Communications AstraZeneca, Daiichi Sankyo, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd). The survival …
News

Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment

May 22, 2024 Medical Communications Crohn’s disease, Eli Lilly, Endocrinology, clinical trial, mirikizumab

Eli Lilly has announced results from its pivotal phase 3 VIVID-1 study, which assessed patients with moderately to severely active …
News

J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study

May 21, 2024 Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis

Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …
News

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024 Medical Communications Amgen, FDA, Oncology, lung cancer

Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) for the treatment of adult …
News

FDA approves Roche’s HPV self-collection screening option

May 15, 2024 Medical Communications FDA, HPV, Oncology, Roche, cervical cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-collection solution. This …
News

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

May 14, 2024 Medical Communications ATTR-CM, Cardiology, NHS, Pfizer, tafamidis

NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).
News

Moderna shares update on RSV vaccine

May 13, 2024 Medical Communications FDA, Immunology, Moderna, Vaccine

Moderna has announced that the US Food and Drug Administration (FDA) has shared that it will not complete its review …
News

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024 Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …
News

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024 Medical Communications COPD, Cardiology, clinical trial, verona pharma

Verona Pharma has announced that it will share eight posters at the American Thoracic Society International Conference (ATS) 2024, including …
News
anirudh-djo3injpaoe-unsplash_3

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024 Medical Communications FDA, Haematology, Pfizer, haemophilia

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of …
News

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

April 29, 2024 Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …
News

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024 Medical Communications Ascendis Pharma, Internal Medicine, MHRA, hypoparathyroidism

Ascendis Pharma has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Yorvipath …
News

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024 Medical Communications FDA, GSK, Oncology, endometrial cancer, sBLA

GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025